ClinicalTrials.gg
CompletedNCT01708902Updated Apr 24, 2015Results posted

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

A Phase 3 interventional study of linagliptin2.5mg/metformin1000mg and linagliptin2.5mg/metformin1000mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 56 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-24.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
876
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
7th of 67
876 · median 175
Started
2012
with 5 others
Phase 3
31 of 67
none open now
Registered
31st of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 6 that started in 2012, is one of 31 in phase 3, and was the 31st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Type 2 diabetes mellitus(T2DM) prior to
  2. Male and female patients on diet and exercise regimen who are drug-naïve
  3. Glycosylated (HbA1c) at V1a >/=7.5 %\<11% for main group and HbA1c >/= 11.0 % for the additional parallel group
  4. Age >/= 18 and \</= 80 years at Visit 1a (Screening)
  5. (BMI)\</ = 40 kg/m2 at Visit 1a (Screening)
  6. Signed and dated written informed consent by date of Visit 1a in accordance with good clinical practice(GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  1. Uncontrolled hyperglycaemia required for rescue medication during placebo run-in phase
  2. In main group, the patients with medicinal product(IMP) compliance \< 80 % or >120 % during 2 weeks placebo run in period
  3. Acute coronary syndrome stroke or (TIA) within 3 months prior to randomisation
  4. Impaired hepatic function, defined by serum levels of either (ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP) above 3 x (ULN) ,or total above 1.5 x ULN as determined at Visit 1a
  5. Known or allergy to linagliptin or its or metformin or placebo
  6. Treatment with anti-obesity drugs 3 months prior to or any other treatment at the time of screening
  7. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.
  8. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form or during the trial.
  9. Pre-menopausal women (last menstruation \</= 1 year prior to informed consent) who are nursing or pregnant or are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study
  10. Current treatment with systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
  11. Renal failure or renal impairment at Visit 1a (screening) with an Estimated (eGFR) \< 60 ml/min
  12. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
  13. Dehydration by clinical judgement of the investigator
  14. Clinical detected unstable or acute congestive heart failure
  15. Acute or chronic metabolic acidosis (present in patient history)
  16. Hereditary galactose intolerance
  17. Known history of pancreatitis and chronic pancreatitis
  18. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within last 5 years.
  19. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial at the discretion of investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double
Enrollment
876 participants (actual)

Study arms

  • Experimental
    linagliptin2.5mg / metformin500mg BID

    patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID

    Drug: linagliptin 5mg · Drug: Metformin 500mg

  • Experimental
    linagliptin2.5mg / metformin1000mg BID

    patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID

    Drug: linagliptin 5mg · Drug: Metformin 1000mg

  • Active comparator
    metformin 500mg BID

    patient to receive a tablet containing metformin 500mg BID

    Drug: linagliptin2.5mg/metformin500mg

  • Active comparator
    metformin 1000mg BID

    patient to receive a tablet containing metformin 1000mg BID

    Drug: linagliptin2.5mg/metformin1000mg

  • Active comparator
    linagliptin 5 mg QD

    patient to receive a tablet containing linagliptin 5mg once daily

    Drug: linagliptin2.5mg/metformin1000mg · Drug: linagliptin2.5mg/metformin500mg

Interventions

  • Druglinagliptin2.5mg/metformin1000mg

    linagliptin2.5mg/metformin1000mg BID

  • Druglinagliptin2.5mg/metformin1000mg

    linagliptin2.5mg/metformin1000mg BID

  • linagliptin 5mg once daily

  • Metformin 500mg BID

  • Druglinagliptin2.5mg/metformin500mg

    linagliptin2.5mg/metformin500mg BID

  • Druglinagliptin2.5mg/metformin500mg

    linagliptin2.5mg/metformin500mg BID

  • linagliptin 5mg once daily

  • Metformin 1000mg BID

06

What researchers measure

Primary outcomes

  1. The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group

    The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.

    Time frame: Baseline and week 24

  2. The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)

    The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases \[OC\]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment\*week. The sensitivity analysis was added as the primary analysis failed with borderline results.

    Time frame: Baseline and week 24

  3. The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG

    The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.

    Time frame: Baseline and week 12

Secondary outcomes

  1. The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group

    The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 24 weeks of treatment in main group.

    Time frame: Week 24 (after first drug administration)

  2. The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG

    The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 12 weeks of treatment in APG.

    Time frame: Week 12 (after first drug administration)

  3. The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group

    The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 24 weeks of treatment in main group.

    Time frame: Week 24 (after first drug administration)

  4. The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG

    The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 12 weeks of treatment in APG.

    Time frame: Week 12 (after first drug administration)

  5. The Occurrence of Relative Efficacy Response in Main Group

    The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group

    Time frame: From baseline until week 24

  6. The Occurrence of Relative Efficacy Response in APG

    The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG

    Time frame: From baseline until week 12

  7. The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group

    The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.

    Time frame: Baseline and week 24

  8. The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG

    The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.

    Time frame: Baseline and week 12

  9. The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group

    The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.

    Time frame: From baseline until week 24

  10. The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG

    The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.

    Time frame: From baseline until week 12

07

Results

Posted Apr 24, 2015

Participant flow

Participant flow — Overall Study
MilestoneMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BIDAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
Started1471451441471477172
Completed1301371271371316465
Not completed17817101677
Withdrew: Adverse event3492735
Withdrew: Lack of efficacy3100010
Withdrew: Non compliance with protocol0213000
Withdrew: Lost to follow-up2122001
Withdrew: Refused to continue trial medication8042811
Withdrew: Other reason1011120

Outcome measures

PrimaryThe Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group

The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.

Time frame:
Baseline and week 24
Reported as:
Mean · percentage
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group
percentageMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group-1.29 ± 0.08-1.64 ± 0.08-2.07 ± 0.08-2.15 ± 0.08-2.29 ± 0.08
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = 0.0587 · Mean difference (final values): -0.22 · 95% CI -0.45 to 0.01The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Metformin 1000mg BID'.
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -1.00 · 95% CI -1.23 to -0.78The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Linagliptin 5mg QD'.
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.51 · 95% CI -0.73 to -0.29The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' minus 'Main: Metformin 500mg BID'.
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.87 · 95% CI -1.09 to -0.64The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' minus 'Main: Linagliptin 5mg QD'.
SecondaryThe Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group

The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 24 weeks of treatment in main group.

Time frame:
Week 24 (after first drug administration)
Reported as:
Number · percentage of participants
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group
percentage of participantsMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group43.6 (35.2 to 52.2)50.0 (41.6 to 58.4)69.0 (60.3 to 76.8)72.1 (63.9 to 79.4)77.1 (69.3 to 83.8)
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0771 · Odds ratio (or): 1.673 · 95% CI 0.946 to 2.961
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.489 · 95% CI 3.164 to 9.522
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.829 · 95% CI 1.678 to 4.767
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.818 · 95% CI 2.259 to 6.454
SecondaryThe Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG

The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 12 weeks of treatment in APG.

Time frame:
Week 12 (after first drug administration)
Reported as:
Number · percentage of participants
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG
percentage of participantsAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG27.1 (17.2 to 39.1)58.8 (46.2 to 70.6)
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0001 · Odds ratio (or): 4.169 · 95% CI 1.997 to 8.701
SecondaryThe Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group

The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 24 weeks of treatment in main group.

Time frame:
Week 24 (after first drug administration)
Reported as:
Number · percentage of participants
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group
percentage of participantsMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group23.4 (16.7 to 31.3)34.7 (27.0 to 43.1)50.4 (41.6 to 59.2)56.3 (47.8 to 64.6)60.3 (51.7 to 68.4)
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0480 · Odds ratio (or): 1.661 · 95% CI 1.004 to 2.746
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.923 · 95% CI 3.452 to 10.164
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = 0.0002 · Odds ratio (or): 2.574 · 95% CI 1.563 to 4.239
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.682 · 95% CI 2.751 to 7.968
SecondaryThe Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG

The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 12 weeks of treatment in APG.

Time frame:
Week 12 (after first drug administration)
Reported as:
Number · percentage of participants
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG
percentage of participantsAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG15.7 (8.1 to 26.4)36.8 (25.4 to 49.3)
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0062 · Odds ratio (or): 3.135 · 95% CI 1.383 to 7.110
PrimaryThe Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)

The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases \[OC\]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment\*week. The sensitivity analysis was added as the primary analysis failed with borderline results.

Time frame:
Baseline and week 24
Reported as:
Mean · percentage
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)
percentageMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)-1.34 ± 0.08-1.68 ± 0.08-2.08 ± 0.08-2.16 ± 0.08-2.38 ± 0.08
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = 0.0109 · Mean difference (final values): -0.30 · 95% CI -0.53 to -0.07The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Metformin 1000mg BID'.
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -1.04 · 95% CI -1.27 to -0.81The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Linagliptin 5mg QD'.
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.47 · 95% CI -0.70 to -0.24The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID ' minus 'Main: Metformin 500mg BID' .
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -0.81 · 95% CI -1.04 to -0.58The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' minus 'Main: Linagliptin 5mg QD'.
PrimaryThe Change From Baseline in HbA1c After 12 Weeks of Treatment in APG

The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.

Time frame:
Baseline and week 12
Reported as:
Mean · percentage
The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG
percentageAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG-3.46 ± 0.22-4.71 ± 0.22
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = 0.0001 · Mean difference (final values): -1.25 · 95% CI -1.87 to -0.63The adjusted mean difference was calculated as the adjusted mean of 'APG: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'APG: Linagliptin 5mg QD'.
SecondaryThe Occurrence of Relative Efficacy Response in Main Group

The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group

Time frame:
From baseline until week 24
Reported as:
Number · percentage of participants
The Occurrence of Relative Efficacy Response in Main Group
percentage of participantsMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Relative Efficacy Response in Main Group73.0 (64.9 to 80.2)80.6 (73.1 to 86.7)89.5 (83.0 to 94.1)93.0 (87.4 to 96.6)89.4 (83.1 to 93.9)
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.9705 · Odds ratio (or): 0.986 · 95% CI 0.456 to 2.130
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0007 · Odds ratio (or): 3.093 · 95% CI 1.612 to 5.938
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = 0.0029 · Odds ratio (or): 3.190 · 95% CI 1.486 to 6.849
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.871 · 95% CI 2.318 to 10.238
SecondaryThe Occurrence of Relative Efficacy Response in APG

The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG

Time frame:
From baseline until week 12
Reported as:
Number · percentage of participants
The Occurrence of Relative Efficacy Response in APG
percentage of participantsAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Occurrence of Relative Efficacy Response in APG84.3 (73.6 to 91.9)91.2 (81.8 to 96.7)
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.2523 · Odds ratio (or): 1.865 · 95% CI 0.642 to 5.420
SecondaryThe Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group

The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.

Time frame:
Baseline and week 24
Reported as:
Mean · mg/dL
The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group
mg/dLMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group-15.03 ± 2.25-29.87 ± 2.23-42.07 ± 2.31-39.33 ± 2.24-47.44 ± 2.26
Statistical analysis
  • Main: Metformin 1000mg BID vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = 0.0971 · Mean difference (final values): -5.37 · 95% CI -11.72 to 0.98The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Metformin 1000mg BID'.
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -32.42 · 95% CI -38.67 to -26.16The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'Main: Linagliptin 5mg QD'.
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = 0.0028 · Median difference (net): -9.47 · 95% CI -15.66 to -3.27The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' minus 'Main: Metformin 500mg BID'.
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · ANCOVA · p = <0.0001 · Mean difference (final values): -24.31 · 95% CI -30.54 to -18.08The adjusted mean difference was calculated as the adjusted mean of 'Main: Linagliptin 2.5mg / Metformin 500mg BID' minus 'Main: Linagliptin 5mg QD'.
SecondaryThe Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG

The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.

Time frame:
Baseline and week 12
Reported as:
Mean · mg/dL
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG
mg/dLAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG-56.70 ± 6.53-91.92 ± 6.48
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · ANCOVA · p = 0.0002 · Mean difference (final values): -35.21 · 95% CI -53.48 to -16.95The adjusted mean difference was calculated as the adjusted mean of 'APG: Linagliptin 2.5mg / Metformin 1000mg BID' minus 'APG: Linagliptin 5mg QD'.
SecondaryThe Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group

The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.

Time frame:
From baseline until week 24
Reported as:
Number · percentage of participants
The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group
percentage of participantsMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BID
The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group7.1 (3.5 to 12.7)2.1 (0.4 to 6.0)0.0 (0.0 to 2.7)1.4 (0.2 to 5.0)2.1 (0.4 to 6.1)
Statistical analysis
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0271 · Odds ratio (or): 0.209 · 95% CI 0.052 to 0.838
  • Main: Metformin 500mg BID vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = 0.9699 · Odds ratio (or): 0.965 · 95% CI 0.150 to 6.202
  • Main: Linagliptin 5mg QD vs Main: Linagliptin 2.5mg / Metformin 500mg BID · Regression, Logistic · p = 0.0343 · Odds ratio (or): 0.183 · 95% CI 0.038 to 0.882
SecondaryThe Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG

The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.

Time frame:
From baseline until week 12
Reported as:
Number · percentage of participants
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG
percentage of participantsAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BID
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG10.0 (4.1 to 19.5)1.5 (0.0 to 7.9)
Statistical analysis
  • APG: Linagliptin 5mg QD vs APG: Linagliptin 2.5mg / Metformin 1000mg BID · Regression, Logistic · p = 0.0474 · Odds ratio (or): 0.114 · 95% CI 0.013 to 0.976

Adverse events

Collected over From first drug administration (week 1) until end of treatment, up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main: Linagliptin 5mg QD—2/147 (1.4%)30/147 (20.4%)
Main: Metformin 500mg BID—1/145 (0.7%)31/145 (21.4%)
Main: Metformin 1000mg BID—2/144 (1.4%)42/144 (29.2%)
Main: Linagliptin 2.5mg / Metformin 500mg BID—1/147 (0.7%)32/147 (21.8%)
Main: Linagliptin 2.5mg / Metformin 1000mg BID—4/147 (2.7%)41/147 (27.9%)
APG: Linagliptin 5mg QD up to Week 12—1/71 (1.4%)20/71 (28.2%)
APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12—1/72 (1.4%)15/72 (20.8%)
APG: Linagliptin 5mg After Week 12—0/33 (0%)2/33 (6.1%)
APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12—1/31 (3.2%)9/31 (29%)
APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12—1/65 (1.5%)9/65 (13.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BIDAPG: Linagliptin 5mg QD up to Week 12APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12APG: Linagliptin 5mg After Week 12APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12
GastritisGastrointestinal disorders0/1470/1450/1440/1470/1470/710/720/331/310/65
PharyngotonsillitisInfections and infestations0/1470/1450/1440/1470/1470/710/720/330/311/65
Septic shockInfections and infestations0/1470/1450/1440/1470/1470/710/720/330/311/65
Urinary tract infectionInfections and infestations0/1470/1450/1440/1470/1470/710/720/330/311/65
DehydrationMetabolism and nutrition disorders0/1470/1450/1440/1470/1470/710/720/330/311/65
Renal failure acuteRenal and urinary disorders0/1470/1450/1440/1470/1470/710/720/330/311/65
Cerebral infarctionNervous system disorders0/1470/1450/1440/1470/1471/710/720/330/310/65
PneumoniaInfections and infestations0/1470/1450/1440/1470/1470/711/720/330/310/65
Acute coronary syndromeCardiac disorders0/1470/1451/1440/1470/1470/710/720/330/310/65
OtosclerosisEar and labyrinth disorders0/1470/1451/1440/1470/1470/710/720/330/310/65
Most frequent other events
Most frequent other events
EventMain: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BIDAPG: Linagliptin 5mg QD up to Week 12APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12APG: Linagliptin 5mg After Week 12APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12
HyperuricaemiaMetabolism and nutrition disorders11/14713/14513/1448/14711/1474/714/721/336/314/65
HyperglycaemiaMetabolism and nutrition disorders7/1474/1450/1444/1472/14712/712/720/332/312/65
DiarrhoeaGastrointestinal disorders5/1478/14516/1447/14714/1472/714/721/331/311/65
Upper respiratory tract infectionInfections and infestations6/1476/14514/14412/14711/1472/714/720/331/311/65
DyslipidaemiaMetabolism and nutrition disorders2/1473/1454/1445/14710/1471/710/720/330/310/65
DizzinessNervous system disorders3/1472/1457/1443/1476/1471/712/720/332/310/65
NasopharyngitisInfections and infestations2/1472/1453/1442/1474/1474/712/720/330/311/65

Baseline characteristics

Treated set (TS): all patients treated with at least 1 dose of study medication

Age, Continuous
Age, Continuous(years)Main: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BIDAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BIDTotal
Mean50.8 ± 10.552.1 ± 9.651.4 ± 10.451.4 ± 10.250.7 ± 9.449.5 ± 11.649.9 ± 11.751.0 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Main: Linagliptin 5mg QDMain: Metformin 500mg BIDMain: Metformin 1000mg BIDMain: Linagliptin 2.5mg / Metformin 500mg BIDMain: Linagliptin 2.5mg / Metformin 1000mg BIDAPG: Linagliptin 5mg QDAPG: Linagliptin 2.5mg / Metformin 1000mg BIDTotal
Female71545355602332348
Male76919192874840525
08

Study locations

56 sites
  • 1288.18.86001 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1288.18.86002 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1288.18.86003 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1288.18.86004 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1288.18.86046 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1288.18.86019 Boehringer Ingelheim Investigational Site
    Changchun, China
  • 1288.18.86020 Boehringer Ingelheim Investigational Site
    Changchun, China
  • 1288.18.86028 Boehringer Ingelheim Investigational Site
    Changsha, China
  • 1288.18.86029 Boehringer Ingelheim Investigational Site
    Changsha, China
  • 1288.18.86050 Boehringer Ingelheim Investigational Site
    Changsha, China
  • 1288.18.86045 Boehringer Ingelheim Investigational Site
    Chengdu, China
  • 1288.18.86042 Boehringer Ingelheim Investigational Site
    Chongqing, China
  • 1288.18.86023 Boehringer Ingelheim Investigational Site
    Dalian, China
  • 1288.18.86009 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 1288.18.86010 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 1288.18.86012 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 1288.18.86047 Boehringer Ingelheim Investigational Site
    Haerbin, China
  • 1288.18.86032 Boehringer Ingelheim Investigational Site
    Hefei, China
  • 1288.18.86016 Boehringer Ingelheim Investigational Site
    Hengshui, China
  • 1288.18.86017 Boehringer Ingelheim Investigational Site
    Jinan, China
  • 1288.18.86026 Boehringer Ingelheim Investigational Site
    Lanzhou, China
  • 1288.18.86034 Boehringer Ingelheim Investigational Site
    Nan Ning, China
  • 1288.18.86039 Boehringer Ingelheim Investigational Site
    Nanchang, China
  • 1288.18.86035 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 1288.18.86036 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 1288.18.86006 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1288.18.86007 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1288.18.86008 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1288.18.86013 Boehringer Ingelheim Investigational Site
    Shantou, China
  • 1288.18.86022 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 1288.18.86014 Boehringer Ingelheim Investigational Site
    Shijiazhuang, China
  • 1288.18.86015 Boehringer Ingelheim Investigational Site
    Shijiazhuang, China
  • 1288.18.86038 Boehringer Ingelheim Investigational Site
    Suzhou, China
  • 1288.18.86049 Boehringer Ingelheim Investigational Site
    Wuhan, China
  • 1288.18.86033 Boehringer Ingelheim Investigational Site
    Wuhu, China
  • 1288.18.86024 Boehringer Ingelheim Investigational Site
    Xi'An, China
  • 1288.18.86025 Boehringer Ingelheim Investigational Site
    Xi'An, China
  • 1288.18.86030 Boehringer Ingelheim Investigational Site
    Yueyang, China
  • 1288.18.60004 Boehringer Ingelheim Investigational Site
    Kelantan, Malaysia
  • 1288.18.60002 Boehringer Ingelheim Investigational Site
    Melaka, Malaysia
  • 1288.18.60005 Boehringer Ingelheim Investigational Site
    Negeri Sembilan, Malaysia
  • 1288.18.60007 Boehringer Ingelheim Investigational Site
    Negeri Sembilan, Malaysia
  • 1288.18.60001 Boehringer Ingelheim Investigational Site
    Perak, Malaysia
  • 1288.18.60006 Boehringer Ingelheim Investigational Site
    Perak, Malaysia
  • 1288.18.60008 Boehringer Ingelheim Investigational Site
    Putrajaya, Malaysia
  • 1288.18.60003 Boehringer Ingelheim Investigational Site
    Selangor, Malaysia
  • 1288.18.63003 Boehringer Ingelheim Investigational Site
    Cebu City, Philippines
  • 1288.18.63007 Boehringer Ingelheim Investigational Site
    Cebu, Philippines
  • 1288.18.63002 Boehringer Ingelheim Investigational Site
    Makati City, Philippines
  • 1288.18.63001 Boehringer Ingelheim Investigational Site
    Manila, Philippines
  • 1288.18.63008 Boehringer Ingelheim Investigational Site
    Quezon City, Philippines
  • 1288.18.63006 Boehringer Ingelheim Investigational Site
    Surigao, Philippines
  • 1288.18.63005 Boehringer Ingelheim Investigational Site
    Tagum City, Philippines
  • 1288.18.84003 Boehringer Ingelheim Investigational Site
    Hanoi, Vietnam
  • 1288.18.84001 Boehringer Ingelheim Investigational Site
    Ho Chi Minh City, Vietnam
  • 1288.18.84002 Boehringer Ingelheim Investigational Site
    Ho Chi Minh City, Vietnam
09

References and documents

Publications

  • Lv Q, Shen J, Miao L, Ye B, Schepers C, Plat A, Shi Y. Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c </= 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials. Diabetes Ther. 2020 Jun;11(6):1317-1330. doi: 10.1007/s13300-020-00819-9. Epub 2020 Apr 23. PubMed 32328953 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 17, 2012
Start
Oct 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Apr 24, 2015
Last update
Apr 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01708902
Responsible party
Sponsor
First posted
Oct 17, 2012
Start date
Oct 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Apr 24, 2015
Last update
Apr 24, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion